Skip to main content
Reimbursement strategy

Cost-effective market access strategy for medical technologies in Europe

A holistic approach to reimbursement strategies trusted by global market leaders and SMEs

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Publication Digest: Quantitative Benefit-Risk Assessment in Medical Product Decision Making: A Good Practices Report of an ISPOR Task Force

12 Jul 2023

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent publication, Tervonen et al. aimed to establish good practices for developing rigorous quantitative benefit-risk assessments (qBRAs) and provide a checklist for their reporting. The study outlines the five main steps of qBRA development, including formulating the research question, selecting appropriate analysis models, evaluating attribute sets, choosing preference elicitation methods, and effectively communicating the results. In addition, the authors provided recommendations on each step and discussed suitable methods for preference elicitation, such as discrete choice experiments, threshold technique, and swing weighting.

Access the full-text article here.